<DOC>
	<DOCNO>NCT00000866</DOCNO>
	<brief_summary>To evaluate safety administer Therion Recombinant Vaccinia-HIV-1 IIIB env/gag/pol Vaccine ( TBC-3B ) vaccination vaccinia-naive individual . To evaluate immunogenicity prim TBC-3B scarification , intradermal , subcutaneous route , follow booster immunization MN rgp120 HIV-1 . To compare immunogenicity prim TBC-3B vaccinia-naive individual vaccinia-immune individual . In prior trial evaluate alternative method vaccine administration , scarification find imprecise method administration allow 1.0 - 2.5 microliters immunogen give . Since feasible produce vaccine concentration higher 10 10th pfu/ml , method limit maximum deliverable dose . Intradermal subcutaneous injection route allow large volume vaccinia give , i.e . : 200 microliters intradermally 100 ml subcutaneously . In present study , initial prim dose administer 3 method ; however , second prim dose administer 2 month intradermally subcutaneously 2 log high order achieve boost immune response , particularly gag pol component TBC-3B .</brief_summary>
	<brief_title>A Multicenter , Randomized , Placebo-Controlled , Double-Blind Trial Evaluate Safety Immunogenicity Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine ( TCB-3B ) MN RGP 120/HIV-1 In Alum .</brief_title>
	<detailed_description>In prior trial evaluate alternative method vaccine administration , scarification find imprecise method administration allow 1.0 - 2.5 microliters immunogen give . Since feasible produce vaccine concentration higher 10 10th pfu/ml , method limit maximum deliverable dose . Intradermal subcutaneous injection route allow large volume vaccinia give , i.e . : 200 microliters intradermally 100 ml subcutaneously . In present study , initial prim dose administer 3 method ; however , second prim dose administer 2 month intradermally subcutaneously 2 log high order achieve boost immune response , particularly gag pol component TBC-3B . After volunteer recruit , screen enrol study , randomize group C , D , E. Each group enroll 10 patient 2 control . The placebo control TBC-3B standard vaccinia vaccination administer dos higher administered scarification ; placebo control MN rgp120 alum . Group C receive undiluted TBC-3B scarification , month 0 2 . Group D receive dilute TBC-3B intradermally month 0 undiluted TBC-3B month 2 . Group E receive dilute TBC-3B subcutaneously month 0 undiluted TBC-3B month 2 . At month 8 12 group receive MN rgp 120/HIV-1 alum intramuscularly .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Patients must : Negative FDAapproved ELISA HIV within 8 week immunization . Normal history physical examination . Negativity Hepatitis B surface antigen . Availability followup plan duration study ( 18 month ) . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Medical psychiatric condition occupational responsibility preclude subject compliance protocol . Specifically excluded people history suicide attempt , recent suicidal ideation past present psychosis . Active syphilis . NOTE : If serology document false positive due remote ( &gt; 6 month ) treat infection , volunteer eligible . Active tuberculosis . NOTE : Patients positive PPD normal chest Xray show evidence TB require INH therapy eligible . Household contact , occupational exposure , people follow : Pregnancy . &lt; 12 month age . Eczema Immunodeficiency disease . Use immunosuppressive medication . Patients follow prior condition exclude : History immunodeficiency , chronic illness , malignancy autoimmune disease . History cancer , unless surgical excision follow sufficient observation period give reasonable assurance cure . Any history anaphylaxis history serious adverse reaction vaccine . History serious allergic reaction substance , require hospitalization emergent medical care ( e.g. , StevensJohnson syndrome , bronchospasm , hypotension ) . Eczema within past year . History smallpox vaccination . Envelope band HIV1 Western blot within 8 week immunization . Prior Medication : Excluded : Use immunosuppressive . Live attenuate vaccine within 60 day study . NOTE : Medically indicate subunit kill vaccine ( e.g . influenza , pneumococcal ) exclude , give least 2 week prior HIV immunization . Experimental agent within 30 day prior study . Prior receipt HIV1 vaccine placebo recipient previous HIV vaccine trial . Receipt blood product immunoglobulin within past 6 month . Risk Behavior : Excluded : History injection drug use within last 12 month prior enrollment . Higher intermediate risk sexual behavior define AVEG . Lower risk sexual behavior define AIDS Vaccine Evaluation Group ( AVEG ) procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Vaccinia Virus</keyword>
	<keyword>Placebos</keyword>
	<keyword>HIV-1</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Genes , env</keyword>
	<keyword>Genes , pol</keyword>
	<keyword>Genes , gag</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>